YAP1 and breast carcinoma: It was shown that the inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in the mevalonate pathway, sequesters YAP and TAZ in the cytoplasm of breast cancer cells, leading to decreased YAP/TAZ transcriptional activation, and impaired YAP/TAZ-mediated biological effects such as cell proliferation, cancer stem cell self-renewal, and cell migration [61].